HHGA
DNLI icon

Halbert Hargrove Global Advisors’s Denali Therapeutics DNLI Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-104
Closed -$1.51K – 468
2025
Q3 		$1.51K Buy
+104
New +$1.49K ﹤0.01% 618

Other funds holding DNLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Halbert Hargrove Global Advisors's DNLI Position: Q4 2025 in Review

Halbert Hargrove Global Advisors sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 104 shares — an estimated $1.51K sold.

Halbert Hargrove Global Advisors first reported a position in DNLI in Q3 2025 and held it in 1 quarter. The position peaked at $1.51K in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

  • Halbert Hargrove Global Advisors reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 104 Denali Therapeutics shares in Q4 2025, an estimated $1.51K.
  • Halbert Hargrove Global Advisors first reported a position in Denali Therapeutics in Q3 2025 and held it in 1 quarter.
  • Halbert Hargrove Global Advisors's Denali Therapeutics position peaked at $1.51K in Q3 2025.
  • 250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Halbert Hargrove Global Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.